Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review
Christine E Garnett1, Nhi Beasley, V Atul Bhattaram
1Office of Clinical Pharmacology, Center of Drug Evaluation and Reseach, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20903-0002, USA. christine.garnett@fda.hhs.gov
Abstract:
The criterion for assessing whether a drug prolongs QT as described in the International Conference on Harmonization topic E14 guideline does not explicitly account for individual drug concentrations. The authors' experience with reviewing QT studies indicates that understanding the relationship, if any, between individual drug concentration and QT change provides important additional information to support regulatory decision making. Therefore, regulatory reviews of "thorough QT" studies routinely include a characterization of the concentration-QT relationship. The authors provide examples to illustrate how the concentration-QT relationship has been used to plan and interpret the thorough QT study, to evaluate QT risk for drugs that have no thorough QT studies, to assess QT risk in subpopulations, to make dose adjustments, and to write informative drug labels.
Related Concept Videos
Pharmacodynamic Models: Linear Concentration–Effect Model
Dysrhythmias V: Evaluating Dysrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Drug Concentration Versus Time Correlation
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the lowest drug...

